The Comparison Of Therapeutic Effect And Security Between CSⅡ And MDI In Type 2 Diabetes Mellitus

Objective: In recent years, intensive treatment is becoming more and more widely recognized by clinicians. A number of meta-analysis showed that continuous subcutaneous insulin infusion (CSII), as an important part of intensive treatment, can be effective and safe for blood glucose control of diabetes mellitus (DM) patients. 1292 type 2 diabetic patients were divided into continuous subcutaneous insulin infusion (CSII) group and multiple daily injection (MDI) group according to their treatments in hospital, then compare the therapeutic effect and security between the two groups through retrospectively analyzing those patients information.Method: 1292 type 2 diabetic patients, selected from March 2009 to December 2010 in Dalian municipal central hospital, were divided into continuous subcutaneous insulin infusion (CSII) group and multiple daily injection (MDI) group according to their treatments in hospital. Compare the therapeutic effect and security between the two groups before and after treatment. Meanwhile, based on the two baseline characteristics with significant differences, each group was divided into four sub-groups to compare.Results: In CSII group, the fasting blood glucose (FBG) from the 12.7±1.9 significantly decreased to 7.5±1.9 after treatment(P<0.05), the 2-hour postprandial blood glucose (2hBG) from the 13.8±4.6 significantly decreased to 8.1±2.1 after treatment(P<0.05). In MDI group, the fasting blood glucose (FBG) from the 13.1±4.8 significantly decreased to 7.2±1.7 after treatment(P<0.05), the 2-hour postprandial blood glucose (2hBG) from the 14.4±4.6 significantly decreased to 8.5±2.0 after treatment(P<0.05).Before treatment there was no significant difference was observed in FBG and 2hBG among the two groups, but after treatment there were statistical differences ( P<0.05).CSII group needed 5.4±2.8 days to achieve standard blood glucose which is significantly shorter than MDI group (8.4±3.7). CSII group has a compliance rate of 59.5%, significantly higher than MDI group (53.85%). MDI group was greater than CSII in the incidence of hypoglycemia (CSII 16.2% vs. MDI 25.9%). But there was no significant difference in insulin dose and blood glucose fluctuation between the two groups.Conclusions: CSII and MDI therapy were both effective in improving blood glucose control. CSII shows the better therapeutic efficacy and security, shorter time to achieve standard blood glucose, higher compliance rate and lower incidence of hypoglycemia. But the two treatments have the same insulin dose and blood glucose fluctuation.